Listen to the article
The rapid evolution of policy changes and regulatory shifts is reshaping how Americans access and interact with health information online, according to recent developments tracked by health policy experts.
Social media platforms are walking back content moderation practices that were implemented during the pandemic. YouTube announced in September that users previously banned under its COVID-19 or election misinformation policies may create new accounts and potentially re-upload previously restricted content, provided they completed an appeals process by November 9.
This shift reflects YouTube’s move toward what it characterizes as “free expression,” though the platform will continue prohibiting content that “contradicts local health authority guidance about specific health conditions and substances.”
The platform’s policy adjustment follows Republican-led investigations into whether the Biden administration pressured tech companies to remove content, potentially violating First Amendment rights. While the Supreme Court reviewed these allegations in Murthy v. Missouri this year, it ruled only that plaintiffs lacked standing without determining whether content removals violated free speech protections.
Many platforms have since loosened their moderation approaches despite KFF polling showing that 68% of adults believe health misinformation represents a bigger problem than “people being prevented from sharing alternative viewpoints” on social media (31%).
At the state level, New York’s Stop Hiding Hate Act took effect in October, requiring large social media companies operating in the state to publicly disclose their content moderation policies and provide users with reporting mechanisms for violations. The law also mandates biannual reports to the state Attorney General detailing content flagging activities.
Meanwhile, proposed federal legislation could significantly impact how artificial intelligence is regulated. Two bills introduced in Congress aim to establish national rules for AI governance. Senator Ted Cruz’s “SANDBOX Act” would provide AI companies two-year exemptions from existing federal regulations, allowing experimentation while policymakers assess regulatory needs. A separate bill from Representative Michael Baumgartner would prevent most states and municipalities from creating their own AI rules for five years to maintain regulatory consistency.
These proposals follow earlier unsuccessful attempts to establish a ten-year moratorium on AI regulation. While potentially providing regulatory clarity, critics warn these bills could create consumer protection gaps by shielding companies from liability if their products share harmful health information. Several states have already enacted AI regulations that could be undermined by federal preemption.
In medical research, conflicting studies about COVID-19 vaccines’ relationship to cancer have created a complex information landscape. A study published in Nature in late October suggested that mRNA COVID-19 vaccines may prolong the lives of cancer patients receiving immunotherapy. Researchers theorized that the mRNA in vaccines helps activate immune cells throughout the body, potentially enhancing tumor recognition and attack. This research builds on decades of exploration into mRNA’s cancer-fighting potential and has received extensive mainstream media coverage.
Conversely, a separate study examining health insurance records for over 8 million people reported associations between COVID-19 vaccination and increased cancer risks. Epidemiologists have identified methodological flaws in this research, including failure to account for differences in healthcare-seeking behaviors between vaccinated and unvaccinated individuals. The journal has since added a notice acknowledging concerns.
The competing narratives have created divergent online conversations. While most discussions center on research suggesting vaccines may benefit cancer patients, a smaller but influential group cites the correlation study to claim vaccines cause cancer. Children’s Health Defense, founded by HHS Secretary Robert F. Kennedy Jr., has promoted such claims, as have members of the CDC’s Advisory Committee on Immunization Practices.
Health experts emphasize there is no credible evidence linking COVID-19 vaccines to cancer causation. The Global Vaccine Data Network has stated there is no plausible mechanism through which the vaccines could cause cancer, particularly given the short follow-up period in the correlation study.
Other developments affecting health information include the American College of Obstetricians and Gynecologists’ updated clinical guidance recommending clinicians combat birth control misinformation, the New England Journal of Medicine’s launch of “Public Health Alerts” as an alternative to the CDC’s Morbidity and Mortality Weekly Report, and Texas Attorney General Ken Paxton’s lawsuit against Tylenol makers for allegedly hiding risks of prenatal use.
A recent KFF Tracking Poll also found that while use of healthcare apps or websites to manage health information is widespread, most adults remain skeptical of AI chatbots accessing their medical records to provide health information, highlighting ongoing trust issues at the intersection of technology and healthcare.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.


24 Comments
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
The cost guidance is better than expected. If they deliver, the stock could rerate.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Interesting update on Social Media Platforms Tighten Moderation Against False COVID-19 Vaccine-Cancer Claims. Curious how the grades will trend next quarter.
Uranium names keep pushing higher—supply still tight into 2026.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
If AISC keeps dropping, this becomes investable for me.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Nice to see insider buying—usually a good signal in this space.
I like the balance sheet here—less leverage than peers.
Good point. Watching costs and grades closely.
I like the balance sheet here—less leverage than peers.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Good point. Watching costs and grades closely.
Exploration results look promising, but permitting will be the key risk.
Good point. Watching costs and grades closely.
Interesting update on Social Media Platforms Tighten Moderation Against False COVID-19 Vaccine-Cancer Claims. Curious how the grades will trend next quarter.